1. Home
  2. JILL vs ALLO Comparison

JILL vs ALLO Comparison

Compare JILL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JILL
  • ALLO
  • Stock Information
  • Founded
  • JILL 1959
  • ALLO 2017
  • Country
  • JILL United States
  • ALLO United States
  • Employees
  • JILL N/A
  • ALLO N/A
  • Industry
  • JILL Clothing/Shoe/Accessory Stores
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JILL Consumer Discretionary
  • ALLO Health Care
  • Exchange
  • JILL Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • JILL 233.1M
  • ALLO 231.9M
  • IPO Year
  • JILL 2017
  • ALLO 2018
  • Fundamental
  • Price
  • JILL $15.66
  • ALLO $1.10
  • Analyst Decision
  • JILL Buy
  • ALLO Strong Buy
  • Analyst Count
  • JILL 3
  • ALLO 10
  • Target Price
  • JILL $25.00
  • ALLO $8.88
  • AVG Volume (30 Days)
  • JILL 86.7K
  • ALLO 5.8M
  • Earning Date
  • JILL 09-03-2025
  • ALLO 08-13-2025
  • Dividend Yield
  • JILL 2.04%
  • ALLO N/A
  • EPS Growth
  • JILL N/A
  • ALLO N/A
  • EPS
  • JILL 2.24
  • ALLO N/A
  • Revenue
  • JILL $602,968,000.00
  • ALLO N/A
  • Revenue This Year
  • JILL $1.16
  • ALLO N/A
  • Revenue Next Year
  • JILL $1.46
  • ALLO $199.63
  • P/E Ratio
  • JILL $6.98
  • ALLO N/A
  • Revenue Growth
  • JILL N/A
  • ALLO N/A
  • 52 Week Low
  • JILL $13.36
  • ALLO $0.86
  • 52 Week High
  • JILL $36.18
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • JILL 49.93
  • ALLO 42.60
  • Support Level
  • JILL $15.15
  • ALLO $0.99
  • Resistance Level
  • JILL $16.20
  • ALLO $1.11
  • Average True Range (ATR)
  • JILL 0.66
  • ALLO 0.11
  • MACD
  • JILL -0.05
  • ALLO -0.01
  • Stochastic Oscillator
  • JILL 42.13
  • ALLO 23.08

About JILL J. Jill Inc.

J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: